BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19623021)

  • 1. Clinical significance of autoantibody expression in allogeneic stem-cell recipients.
    Moon JH; Lee SJ; Kim JG; Chae YS; Kim SN; Kang BW; Suh JS; Lee KS; Sohn SK
    Transplantation; 2009 Jul; 88(2):242-50. PubMed ID: 19623021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation.
    Wechalekar A; Cranfield T; Sinclair D; Ganzckowski M
    Clin Lab Haematol; 2005 Aug; 27(4):247-9. PubMed ID: 16048492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
    Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
    Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
    Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation.
    Sohn SK; Kim JG; Kim DH; Lee NY; Suh JS; Lee KB
    Bone Marrow Transplant; 2003 Jun; 31(11):967-72. PubMed ID: 12774046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
    Kyriakou C; Canals C; Finke J; Kobbe G; Harousseau JL; Kolb HJ; Novitzky N; Goldstone AH; Sureda A; Schmitz N
    J Clin Oncol; 2009 Aug; 27(24):3951-8. PubMed ID: 19620487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.
    Patriarca F; Skert C; Sperotto A; Zaja F; Falleti E; Mestroni R; Kikic F; Calistri E; Filì C; Geromin A; Cerno M; Fanin R
    Exp Hematol; 2006 Mar; 34(3):389-96. PubMed ID: 16543073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult allogeneic haematopoietic stem cell transplantation: a single centre experience in Malaysia.
    Gan GG; Zakaria Z; Sangkar JV; Haris AR; Bee PC; Chin E; Teh A
    Med J Malaysia; 2008 Oct; 63(4):281-7. PubMed ID: 19385485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
    Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
    Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.
    Tauchmanovà L; De Rosa G; Serio B; Fazioli F; Mainolfi C; Lombardi G; Colao A; Salvatore M; Rotoli B; Selleri C
    Cancer; 2003 May; 97(10):2453-61. PubMed ID: 12733144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.
    Hao B; Gao S; Sang YW; Wang L; Meng XQ; You JY
    J Zhejiang Univ Sci B; 2019 Oct.; 20(10):849-860. PubMed ID: 31489804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.
    Kim DH; Popradi G; Xu W; Gupta V; Kuruvilla J; Wright J; Messner HA; Lipton JH
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):471-82. PubMed ID: 19285635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients.
    Schmid I; Stachel D; Pagel P; Albert MH
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):438-44. PubMed ID: 18342786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
    Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
    Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD.
    Kim DH; Sohn SK; Baek JH; Lee KH; Lee JH; Choi SJ; Shin IH
    Bone Marrow Transplant; 2007 Oct; 40(8):779-84. PubMed ID: 17700602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation: analysis of 17 cases].
    Xu D; Liu QF; Sun J; Fan ZP; Wei YQ; Zhang Y; Ye CX; Meng FY
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):549-53. PubMed ID: 16681886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody analysis in chronic graft-versus-host disease.
    Holmes JA; Livesey SJ; Bedwell AE; Amos N; Whittaker JA
    Bone Marrow Transplant; 1989 Sep; 4(5):529-31. PubMed ID: 2790331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Martin SJ; Audrain MA; Oksman F; Ecoiffier M; Attal M; Milpied N; Esnault VL
    Bone Marrow Transplant; 1997 Jul; 20(1):45-8. PubMed ID: 9232255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.